# TST001

Source: https://onco.cc/drugs/tst001/  
OnCo record `tst001` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

TST001 is a monoclonal antibody from Transcenta Therapeutics (Hangzhou) Co., Ltd., in registered phase 2 trials for metastatic cancer.

## Summary

TST001 is listed on ClinicalTrials.gov as an intervention in 2 registered phase 2 trials sponsored by Transcenta Therapeutics (Hangzhou) Co., Ltd., in metastatic cancer. A monoclonal antibody, as described in the registry record. OnCo records the agent from the registry alone; approvals, results and the sponsor's own description will follow as they are published.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest; registry-only
- Code: TST001
- Modality: Monoclonal antibody
- Mechanism: A monoclonal antibody, as described in the registry record.

## Sources

- ClinicalTrials.gov: trials of TST001: https://clinicaltrials.gov/search?intr=TST001

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- trials: [A Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid Tumors](https://onco.cc/trials/nct04396821/), [A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid Tumors](https://onco.cc/trials/nct04495296/)

---
JSON: https://onco.cc/api/v1/entities/tst001.json